The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Burden of Disease Study of Patients with Neovascular Age-Related Macular Degeneration in Spain
Open accessAbstract
INTRODUCTION: Neovascular age-related macular degeneration (nAMD) is a progressive retinal disease that causes severe and irreversible vision loss. The disease can therefore have a significant impact on the life of patients' and their families. The aim of this study was to evaluate the socio-economic burden of nAMD in Spain. METHODS: The annual cost per patient with nAMD was estimated for the first, second, and third year (or beyond) of treatment since diagnosis. Several cost categories were considered including direct healthcare costs (DHC), direct non-healthcare costs (DNHC), labor productivity losses (LPL), and intangible costs (IC) related to loss of quality of life. The average annual cost per patient was estimated by assigning a unit price or financial proxy to the resources consumed per patient. Reference year of costs was 2021. RESULTS: The mean annual cost of nAMD was estimated at €17,265, €15,403, and €14,465 per patient in the first, second, and third year of treatment after diagnosis. There was an additional one-off cost of €744 associated with the diagnosis of nAMD. DHC accounted for most of the total annual cost per patient independent of the year of treatment since diagnosis (48% in year 1; 42% in year 2; 39% in year 3). Similarly, DNHC had an important contribution to the total costs (32% in year 1; 35% in year 2; 37% in year 3), followed by IC (20% in year 1; 23% in year 2; 24% in year 3), while the contribution of patients' LPL was minimal. CONCLUSION: This study estimated a high economic burden associated with nAMD for patients and their families, the healthcare system, and society at large. There is a need to improve the management of these patients to reduce the impact of nAMD disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Annual productivity loss in patients ranged from $23 to $1,006 [34, 39].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [34]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The loss of productivity, pertaining to the reduction in labour force and wages, among nAMD patients was estimated in two studies [34, 39], and carers in one [37] (Fig. 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, intangible costs related to the impact of the disease on the patient’s quality of life and daily activities were estimated annually at the patient level in one model-based study ($6,185) [34].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most frequent resources accounted for within direct non-medical costs were formal care [34, 38–43, 45] and assistive technologies [34, 37–39, 41–43, 45], followed by transportation [34, 37–39, 42, 45] and subsidies [40–43] (Table 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In terms of informal care costs, they were estimated in two studies [34, 39], ranging from $2,508 to $6,634 per patient per annum.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639
Li, J. Q., Welchowski, T., Schmid, M., Mauschitz, M. M., Holz, F. G., & Finger, R. P. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-314422 · Cited by 381
Economic Note: Cost of illness studies
Byford, S. (2000) · BMJ · doi:10.1136/bmj.320.7245.1335 · Cited by 318
Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias
López Bastida, J., Oliva, J., Antoñanzas, F., García-Altés, A., Gisbert, R., Mar, J., & Puig-Junoy, J. (2010) · Gaceta Sanitaria · doi:10.1016/j.gaceta.2009.07.011 · Cited by 311
Quality of life in age-related macular degeneration: a review of the literature
Mitchell, J., & Bradley, C. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-97 · Cited by 304
Taylor, D. J., Hobby, A. E., Binns, A. M., & Crabb, D. P. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011504 · Cited by 288
Updates on the Epidemiology of Age-Related Macular Degeneration
(2017) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2017251 · Cited by 266
The burden of neovascular age-related macular degeneration: a patient’s perspective
Spooner, K., Mhlanga, C., Hong, T., Broadhead, G., & Chang, A. (2018) · Clinical ophthalmology · doi:10.2147/opth.s185052 · Cited by 121
Lafuma, A., ́zin, A. P. B., Lopatriello, S., Hieke, K., Hutchinson, J., Jeanbat-Mimaud, V., & Berdeaux, G. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624020-00007 · Cited by 71
Research works printed but not linked: 1
- NICE. Age-related macular degeneration: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2018. PMID: 29400919.
Cited by
Zhou, Y., & Xue, F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1507860 · Cited by 6
Emerging strategies in drug repurposing for decreasing the risk of age-related macular degeneration
Zhou, B., Mokhashi, N., & Skondra, D. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2635492 · Cited by 2
Ruiz‐Medrano, J., Puertas, M., Hinojosa-Gonzalez, M., Moreno-Alboran, C., & Ruiz‐Moreno, J. M. (2026) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2026.3800 · Cited by 1
Self-citationWillmington, C., Kirby, A., & Murphy, A. (2025) · Health Economics Review · doi:10.1186/s13561-025-00707-7
Encuesta sobre la situación actual de la terapia intravítrea en España
Garay‐Aramburu, G., Zarranz‐Ventura, J., Escobar-Barranco, J. J., García‐Layana, A., Neila, E. R., Donate-López, J., Cervera-Taulet, E., Calvo-Perez, P., Gómez-Resa, M., Lopez-Galvez, M. I., et al. (2026) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2026.502532
Self-citation
Metadata
- Authors
- Abraldes, M. J., Calvo, P., Gámez Lechuga, M., Merino, M., Martín Lorenzo, T., Maravilla-Herrera, P., Gil Jiménez, B., & Ruiz-Moreno, J. M.
- Affiliations
- Complejo Hospitalario Universitario de Santiago (ES)
- Hospital Universitario Miguel Servet (ES)
- Weber (ES)
- Corresponding author
- Merino, María
- Venue
- Ophthalmology and Therapy
- Published
- 2024-05-21
- Volume
- 13
- Issue
- 7
- Pages
- 1925-1935
- ISSN
- 2193-6528 (ISSN-L)
- 2193-8245
- PMC
- PMC11178696
- OpenAlex
- W4398156621
- Cited by
- 6
- References
- 21
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 1
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Ophthalmology and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Roche Farma S.A.
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- neovascular age-related macular degeneration, economic burden of disease, health care costs, labor productivity loss, quality of life, vision loss, Spain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Burden of Disease Study of Patients with Neovascular Age-Related Macular Degeneration in Spain. https://app.cochat.ai/papers/10.1007/s40123-024-00960-9
- The paper
- Abraldes, M. J., Calvo, P., Gámez Lechuga, M., Merino, M., Martín Lorenzo, T., Maravilla-Herrera, P., Gil Jiménez, B., & Ruiz-Moreno, J. M. (2024). Burden of Disease Study of Patients with Neovascular Age-Related Macular Degeneration in Spain. Ophthalmology and Therapy. https://doi.org/10.1007/s40123-024-00960-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
